Literature DB >> 19041695

Skin fibroblast model to study an impaired glutathione synthesis: consequences of a genetic polymorphism on the proteome.

René Gysin1, Irène M Riederer, Michel Cuénod, Kim Q Do, Beat M Riederer.   

Abstract

An impaired glutathione (GSH) synthesis was observed in several multifactorial diseases, including schizophrenia and myocardial infarction. Genetic studies revealed an association between schizophrenia and a GAG trinucleotide repeat (TNR) polymorphism in the catalytic subunit (GCLC) of the glutamate cysteine ligase (GCL). Disease-associated genotypes of this polymorphism correlated with a decrease in GCLC protein expression, GCL activity and GSH content. To clarify consequences of a decreased GCL activity at the proteome level, three schizophrenia patients and three controls have been selected based on the GCLC GAG TNR polymorphism. Fibroblast cultures were obtained by skin biopsy and were challenged with tert-butylhydroquinone (t-BHQ), a substance known to induce oxidative stress. Proteome changes were analyzed by two dimensional gel electrophoresis (2-DE) and results revealed 10 spots that were upregulated in patients following t-BHQ treatment, but not in controls. Nine corresponding proteins could be identified by MALDI mass spectrometry and these proteins are involved in various cellular functions, including energy metabolism, oxidative stress response, and cytoskeletal reorganization. In conclusion, skin fibroblasts of subjects with an impaired GSH synthesis showed an altered proteome reaction in response to oxidative stress. Furthermore, the study corroborates the use of fibroblasts as an additional mean to study vulnerability factors of psychiatric diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19041695     DOI: 10.1016/j.brainresbull.2008.10.015

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  8 in total

Review 1.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

2.  Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia.

Authors:  Jeffrey K Yao; George G Dougherty; Ravinder D Reddy; Matcheri S Keshavan; Debra M Montrose; Wayne R Matson; Joseph McEvoy; Rima Kaddurah-Daouk
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

Review 3.  Human dermal fibroblasts in psychiatry research.

Authors:  S Kálmán; K A Garbett; Z Janka; K Mirnics
Journal:  Neuroscience       Date:  2016-02-09       Impact factor: 3.590

4.  Oxidative stress and glutathione response in tissue cultures from persons with major depression.

Authors:  Sara A Gibson; Željka Korade; Richard C Shelton
Journal:  J Psychiatr Res       Date:  2012-07-28       Impact factor: 4.791

5.  Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients.

Authors:  Danxin Wang; Amanda Curtis; Audrey C Papp; Susan L Koletar; Michael F Para
Journal:  BMC Med Genomics       Date:  2012-07-23       Impact factor: 3.063

6.  Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response.

Authors:  Pierre Mesdom; Romain Colle; Elise Lebigot; Séverine Trabado; Eric Deflesselle; Bruno Fève; Laurent Becquemont; Emmanuelle Corruble; Céline Verstuyft
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

7.  A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia.

Authors:  H Bentsen; K Osnes; H Refsum; D K Solberg; T Bøhmer
Journal:  Transl Psychiatry       Date:  2013-12-17       Impact factor: 6.222

8.  A Role for the Transcription Factor Nk2 Homeobox 1 in Schizophrenia: Convergent Evidence from Animal and Human Studies.

Authors:  Eva A Malt; Katalin Juhasz; Ulrik F Malt; Thomas Naumann
Journal:  Front Behav Neurosci       Date:  2016-03-30       Impact factor: 3.558

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.